Case study on dizziness treatmentAutoimmune encephalitis with dizziness in children: A case report presented to the otolaryngology department.
Relevant yet complex treatment protocols
We observed a unique case involving an 11-year-old boy who initially came into our otolaryngology department complaining of dizziness and nausea, symptoms often attributed to motion sickness. After receiving treatment for what was thought to be motion sickness, the child developed serious symptoms including vision loss and poor mental performance.
This led to a new diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Our exploration into the treatment revealed that the child received protein therapy in the form of human immunoglobulin combined with other medications. While the medical approach seemed to significantly improve his condition, we must note that the effects of the protein alone cannot be independently established given the combination with other treatments.
Ultimately, the child showed remarkable recovery after 15 days, with improved vision and normal mental responses. This case reinforces the importance of considering serious underlying conditions when evaluating dizziness in children and highlights the potential role of protein treatment in the recovery process, though findings must be viewed cautiously due to the multifactorial nature of the treatment regimen.
Read More
We explored the effectiveness of protein treatment in managing dizziness associated with paraneoplastic cerebellar degeneration (PCD) linked to anti-Yo antibodies. The patient initially presented with symptoms like dizziness, nystagmus, dysarthria, and ataxia, prompting a series of tests. Although the first line of treatment including intravenous immunoglobulin and a methylprednisolone pulse showed some improvement, the relief was temporary.
After discharge, the patient’s symptoms worsened considerably, which led us to re-evaluate their condition. Upon readmission, we confirmed additional antibodies related to cerebellar degeneration. When the second round of steroid treatment did not yield the desired effects, we shifted our strategy to ofatumumab, a therapeutical protein. Remarkably, after just two doses, the patient experienced partial relief from dizziness and other symptoms.
This underscores the potential of protein treatments like ofatumumab in addressing dizziness for patients suffering from specific neurological conditions linked to immune responses. It highlights how a tailored approach can lead to meaningful improvements in symptoms that significantly impact quality of life.
Read More